Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)

Condition(s) studied

Investigational drug(s) / intervention(s)

All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.: The dosage and duration of any drug in this study will be determined by the physician based on local clinical practice and local drug labels. The drugs in this study include, but are not limited to, Obinutuzumab, Rituximab, Bruton tyrosine kinase inhibitors, and Lenalidomide. In this non-interventional study, all treatment drug usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.

Study summary

This study aims to evaluate real-world treatment modalities and their corresponding effectiveness and safety in Chinese patients with marginal zone lymphoma, while also exploratively analyzing patient characteristics and health-related quality of life.

Eligibility

Primary outcome measure(s)

• Progression-free survival — Baseline up to data cut-off (up to approximately 60 months)
  Progression-free survival was defined as the time from the date of diagnosis until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first.

Trial sites (1)

More Ruijin Hospital trials in China

Other trials for the same condition